Navigation Links
Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010

BOSTON, Dec. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company looks forward to a prosperous 2010, following a solid year in 2009, due in great part to its MammoView(TM) instrument line.

In the closing months of 2009, Solos Endoscopy, Inc. has taken the initial steps to obtain the CE Mark for its MammoView(TM) line of surgical endoscopy instruments. This will allow the MammoView(TM) line to be sold throughout the European Economic Union (EEU), which according to a 2009 report published by Frost & Sullivan represents $94 Billion, or 30%, of the worldwide demand for medical instruments.

Solos' focus is to strengthen its domestic market share in the industry through the implementation of several strategies in the New Year. In addition, Solos will continue building product awareness and has retained the services of Advertising Associates International to manage its 2010 marketing, promotional and advertising campaign. Finally, the Company plans to expand its research and development efforts to develop new instrumentation to better assist the physician primarily in the area of breast endoscopy.

"We are excited about the progress that Solos has made in 2009. We look forward to increasing our sales revenues with the implementation of our product awareness campaign while at the same time increasing our research and development efforts," stated Bob Segersten, President of Solos Endoscopy, Inc.

For more details on Solos Endoscopy, Inc's accomplishments in 2009 and expectations for 2010 please visit:

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.

SOURCE Solos Endoscopy, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
3. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
4. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
5. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
6. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
7. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
8. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
9. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
10. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
11. Solos Endoscopy, Inc. Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
Post Your Comments:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):